Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -34,48k | 1,12M | Sale to Issuer | 32,41 | 1,36M | -2,47% |
| 2026-05-22 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 5,28M | Derivative Exercise and Sale | 3,85 - 30,27 | 1,36M | - |
| 2026-05-20 | Mr. Richard PulikCFO | -18,96k | 614,56k | Sale to Issuer | 32,41 | 92,46k | -17,02% |
| 2026-04-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 5,15M | Derivative Exercise and Sale | 3,85 - 29,59 | 1,33M | - |
| 2026-04-17 | Mr. Ilan OrenIndependent Chairman | -95,00 | 2,83k | Sale to Issuer | 29,83 | 105,71k | -0,09% |
| 2026-04-17 | Mr. James C. MomtazeeIndependent Director | -94,00 | 2,80k | Sale to Issuer | 29,83 | 94,88k | -0,10% |
| 2026-04-16 | Mr. Matthew GlineCEO & Director | -289,77k | 8,45M | Verkauf | 29,16 | 82,26k | -77,89% |
| 2026-04-08 | Ms. Jennifer HumesCAO | -13,54k | 384,07k | Verkauf | 28,37 | 84,19k | -13,85% |
| 2026-03-31 | Dr. Frank M. TortiPresident & Vant Chair | -160,04k | 4,43M | Sale to Issuer | 27,70 | 13,58M | -1,17% |
| 2026-03-30 | Mr. Matthew GlineCEO & Director | -97,32k | 2,63M | Derivative Exercise and Sale | 26,41 - 27,70 | 372,03k | - |
| 2026-03-31 | Mr. Matthew GlineCEO & Director | -261,19k | 7,23M | Sale to Issuer | 27,70 | 372,03k | -41,25% |
| 2026-03-30 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -58,39k | 1,58M | Derivative Exercise and Sale | 26,41 - 27,70 | 18,68M | - |
| 2026-03-31 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -158,93k | 4,40M | Sale to Issuer | 27,70 | 18,68M | -0,84% |
| 2026-03-26 | Ms. Meghan M. FitzGeraldIndependent Director | -70,00k | 1,31M | Derivative Exercise and Sale | 8,80 - 27,45 | 28,44k | - |
| 2026-03-20 | Mr. Richard PulikCFO | -1,55k | 42,82k | Sale to Issuer | 27,70 | 56,97k | -2,64% |
| 2026-03-20 | Ms. Jennifer HumesCAO | -14,53k | 402,37k | Sale to Issuer | 27,70 | 97,73k | -12,94% |
| 2026-03-17 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 4,88M | Derivative Exercise and Sale | 3,85 - 28,24 | 1,33M | - |
| 2026-03-16 | Ms. Melissa B. EpperlyIndependent Director | -41,86k | 1,20M | Verkauf | 28,68 | 1,28k | -97,03% |
| 2026-02-20 | Mr. Richard PulikCFO | -1.000,00 | 27,15k | Sale to Issuer | 27,15 | 56,76k | -1,73% |
| 2026-02-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 191,43k | Sale to Issuer | 27,15 | 1,33M | -0,53% |
| 2026-02-19 | Dr. Frank M. TortiPresident & Vant Chair | -3,00M | 70,49M | Derivative Exercise and Sale | 3,85 - 27,51 | 13,74M | - |
| 2026-02-13 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 4,53M | Derivative Exercise and Sale | 3,85 - 26,49 | 1,33M | - |
| 2026-02-11 | QVT Financial LPUnternehmen | -1,23M | 32,66M | Verkauf | 26,49 - 26,76 | 25,16M | -4,65% |
| 2026-02-09 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -651,56k | 8,98M | Derivative Exercise and Sale | 12,68 - 26,47 | 18,84M | - |
| 2026-01-20 | Mr. Ilan OrenIndependent Chairman | -124,00 | 2,85k | Sale to Issuer | 22,98 | 104,90k | -0,12% |
| 2026-01-20 | Mr. James C. MomtazeeIndependent Director | -122,00 | 2,80k | Sale to Issuer | 22,98 | 94,51k | -0,13% |
| 2026-01-20 | Ms. Melissa B. EpperlyIndependent Director | -54,00 | 1,24k | Sale to Issuer | 22,98 | 43,14k | -0,13% |
| 2026-01-12 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,61M | Derivative Exercise and Sale | 3,85 - 21,92 | 1,33M | - |
| 2025-12-29 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -3,20M | 28,90M | Derivative Exercise and Sale | 12,68 - 21,74 | 18,84M | - |
| 2025-12-24 | Dr. Frank M. TortiPresident & Vant Chair | -175,38k | 1,46M | Other Disposition | 22,47 | 0,00 | -100,00% |
| 2025-12-23 | Dr. Eric VenkerPresident & CEO of Immunovant | 156,69k | 603,25k | Derivative Exercise and Retained Stock | 3,85 | 1,33M | 13,37% |
| 2025-12-23 | Dr. Eric VenkerPresident & CEO of Immunovant | -275,00k | 5,12M | Derivative Exercise and Sale | 3,85 - 22,53 | 1,33M | - |
| 2025-12-23 | Mr. Richard PulikCFO | -260,00k | 4,84M | Derivative Exercise and Sale | 3,85 - 22,45 | 52,92k | - |
| 2025-12-23 | Mr. Richard PulikCFO | -146,73k | 3,29M | Verkauf | 22,39 | 52,92k | -73,49% |
| 2025-12-20 | Mr. Richard PulikCFO | -2,13k | 47,71k | Sale to Issuer | 22,41 | 199,66k | -1,06% |
| 2025-12-17 | Dr. Mayukh SukhatmePresident, Chief Investment Officer & Director | -59,51k | 619,53k | Derivative Exercise and Sale | 12,68 - 23,09 | 0,00 | - |
| 2025-12-16 | QVT Financial LPUnternehmen | -1,69M | 39,07M | Verkauf | 22,93 - 23,17 | 26,39M | -6,03% |
| 2025-12-15 | Mr. Matthew GlineCEO & Director | -3,87M | 36,85M | Derivative Exercise and Sale | 4,06 - 21,68 | 82,26k | - |
| 2025-12-11 | Mr. Vivek RamaswamyInsider | -7,37M | 67,92M | Derivative Exercise and Sale | 12,68 - 22,05 | 47,01M | - |
| 2025-12-11 | Mr. Vivek RamaswamyInsider | -1,00 | 21,64 | Other Disposition | 21,64 | 47,01M | -0,00% |
| 2025-12-09 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,40M | Derivative Exercise and Sale | 3,85 - 20,85 | 1,17M | - |
| 2025-11-20 | Mr. Richard PulikCFO | -1,24k | 25,03k | Sale to Issuer | 20,27 | 197,62k | -0,62% |
| 2025-11-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 142,92k | Sale to Issuer | 20,27 | 1,17M | -0,60% |
| 2025-11-19 | QVT Financial LPUnternehmen | -1,30M | 26,30M | Verkauf | 20,16 - 20,25 | 28,08M | -4,42% |
| 2025-11-13 | Mr. Vivek RamaswamyInsider | -1,85M | 37,94M | Verkauf | 20,33 - 20,81 | 47,01M | -3,80% |
| 2025-11-07 | Dr. Eric VenkerPresident & CEO of Immunovant | -200,00k | 3,27M | Derivative Exercise and Sale | 3,85 - 20,22 | 1,17M | - |
| 2025-10-20 | Mr. James C. MomtazeeIndependent Director | -158,00 | 2,80k | Sale to Issuer | 17,74 | 94,02k | -0,17% |
| 2025-10-20 | Mr. Ilan OrenIndependent Chairman | -281,00 | 4,98k | Sale to Issuer | 17,74 | 103,86k | -0,27% |
| 2025-10-15 | Dr. Eric VenkerPresident & CEO of Immunovant | -851,38k | 973,08k | Derivative Exercise and Sale | 15,85 - 17,06 | 1,17M | - |
| 2025-10-09 | Dr. Eric VenkerPresident & CEO of Immunovant | -125,67k | 55,51k | Derivative Exercise and Sale | 15,85 - 16,30 | 1,17M | - |
| 2025-10-06 | Dr. Eric VenkerPresident & CEO of Immunovant | -665,16k | 4,83M | Derivative Exercise and Sale | 3,85 - 16,34 | 1,17M | - |
| 2025-09-28 | Mr. Richard PulikCFO | -2,34k | 35,51k | Sale to Issuer | 15,17 | 196,43k | -1,18% |
| 2025-09-19 | Dr. Eric VenkerPresident & CEO of Immunovant | 1.000,00k | 3,85M | Derivative Exercise and Retained Stock | 3,85 | 1,17M | 601,34% |
| 2025-09-22 | Dr. Eric VenkerPresident & CEO of Immunovant | -562,37k | 6,24M | Derivative Exercise and Sale | 3,85 - 15,01 | 1,17M | - |
| 2025-09-19 | Dr. Eric VenkerPresident & CEO of Immunovant | -1,15M | 17,12M | Verkauf | 14,83 - 14,95 | 1,17M | -49,62% |
| 2025-09-20 | Mr. Richard PulikCFO | -2,13k | 32,02k | Sale to Issuer | 15,04 | 194,19k | -1,08% |
| 2025-09-18 | Mr. Matthew GlineCEO & Director | 3,32k | 49,96k | Kauf | 15,07 | 62,47k | 5,60% |
| 2025-09-10 | Mr. Daniel A. GoldIndependent Director | -5,27k | 72,57k | Other Disposition | 13,77 | 8,95M | -0,06% |
| 2025-09-10 | Mr. James C. MomtazeeIndependent Director | -3,28k | 45,19k | Other Disposition | 13,77 | 93,39k | -3,40% |
| 2025-09-10 | Mr. Ilan OrenIndependent Chairman | -2,04k | 28,13k | Other Disposition | 13,77 | 102,64k | -1,95% |
| 2025-09-10 | Ms. Meghan M. FitzGeraldIndependent Director | -937,00 | 12,90k | Other Disposition | 13,77 | 28,44k | -3,19% |
| 2025-09-10 | Ms. Melissa B. EpperlyIndependent Director | -1,66k | 22,87k | Other Disposition | 13,77 | 41,32k | -3,86% |
| 2025-09-03 | Mr. Vivek RamaswamyInsider | -1,78M | 22,46M | Verkauf | 12,50 - 12,96 | 48,87M | -3,51% |
| 2025-08-28 | Mr. Richard PulikCFO | -2,34k | 27,94k | Sale to Issuer | 11,94 | 192,15k | -1,20% |
| 2025-08-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 787,00k | Derivative Exercise and Sale | 3,85 - 11,72 | 1,31M | - |
| 2025-08-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -7,05k | 82,64k | Sale to Issuer | 11,72 | 1,31M | -0,53% |
| 2025-08-20 | Mr. Richard PulikCFO | -1,24k | 14,47k | Sale to Issuer | 11,72 | 192,32k | -0,64% |
| 2025-07-28 | Mr. Richard PulikCFO | -1,92k | 21,78k | Sale to Issuer | 11,35 | 191,14k | -0,99% |
| 2025-07-21 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 767,00k | Derivative Exercise and Sale | 3,85 - 11,52 | 1,31M | - |
| 2025-07-17 | Mr. James C. MomtazeeIndependent Director | -241,00 | 2,81k | Sale to Issuer | 11,65 | 80,26k | -0,30% |
| 2025-04-17 | Mr. Ilan OrenIndependent Chairman | -115,00 | 1,34k | Sale to Issuer | 11,65 | 88,28k | -0,13% |
| 2025-06-28 | Mr. Richard PulikCFO | -1,65k | 18,83k | Sale to Issuer | 11,39 | 188,48k | -0,87% |
| 2025-06-25 | QVT Financial LPUnternehmen | -36,76M | 0,00 | Other Disposition | - | 29,38M | -55,58% |
| 2025-06-20 | Mr. Richard PulikCFO | -1,50k | 17,21k | Sale to Issuer | 11,45 | 183,48k | -0,81% |
| 2025-06-20 | Dr. Eric VenkerPresident & CEO of Immunovant | -100,00k | 760,00k | Derivative Exercise and Sale | 3,85 - 11,45 | 1,31M | - |
| 2025-06-18 | Mr. Vivek RamaswamyInsider | -1,14M | 13,08M | Verkauf | 11,45 - 11,46 | 50,64M | -2,21% |
| 2025-06-04 | Mr. Vivek RamaswamyInsider | -748,23k | 8,45M | Verkauf | 11,19 - 11,34 | 51,78M | -1,42% |
| 2025-06-02 | Dr. Eric VenkerPresident & CEO of Immunovant | 385,03k | 1,48M | Derivative Exercise and Retained Stock | 3,85 | 1,31M | 41,66% |
| 2025-06-02 | Dr. Eric VenkerPresident & CEO of Immunovant | -1.000,00k | 7,30M | Derivative Exercise and Sale | 3,85 - 11,22 | 1,31M | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
